Google Platform Changes Spur Pharma Rethinking Of Search Engine Ads
This article was originally published in The Tan Sheet
Widespread use of paid ads that display disease-specific website address differing significantly from destination hyperlink for branded product will end in January.
You may also be interested in...
Click-through rate on health condition search results declined dramatically since FDA citations, company says.
Firms will need to redesign sponsored links that appear on Internet search engines or forgo using them at all, food and drug attorneys suggest following the agency's recent cluster of letters citing the promotions
Accelerated Approval Program web page links to searchable databases for accelerated approvals of infectious disease products, vaccines, and other nonmalignant indications. New databases, which include products that converted to regular approval or were withdrawn, are modeled after Oncology Center of Excellence’s cancer drug databases that debuted in 2021.